CN105622746A - Preparation process for extracting human von Willebrand factor from waste of cryoprecipitate extraction blood coagulation factor VIII - Google Patents
Preparation process for extracting human von Willebrand factor from waste of cryoprecipitate extraction blood coagulation factor VIII Download PDFInfo
- Publication number
- CN105622746A CN105622746A CN201610077346.0A CN201610077346A CN105622746A CN 105622746 A CN105622746 A CN 105622746A CN 201610077346 A CN201610077346 A CN 201610077346A CN 105622746 A CN105622746 A CN 105622746A
- Authority
- CN
- China
- Prior art keywords
- cryoprecipitate
- vwf
- chromatography
- liquid
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
Abstract
The invention discloses a preparation process for extracting human von Willebrand factor from waste of cryoprecipitate extraction blood coagulation factor VIII. The preparation process includes: performing one-step Q-Sepharose anion exchange chromatography and one-step affinity chromatography purification to obtain high-purity vWF; collecting the waste of the cryoprecipitate extraction blood coagulation factor VIII, namely liquid flowing out through a chromatography column during preparation of the cryoprecipitate extraction blood coagulation factor VIII as a raw material; after Q-Sepharose ion exchange column chromatography, collecting eluate, and removing residual fibronectin and impurities through gelatin affinity chromatography to obtain the von Willebrand factor. The high-purity von Willebrand factor obtained by the preparation process is reliable in quality and can meet clinical needs on treatment medicine urgently needed by von Willebrand patients. The preparation process is of quite important significance in comprehensive utilization of cryoprecipitate and indirect conservation of scarce plasma resources.
Description
Technical field
The present invention relates to the preparation technology extracting human von willebrand disease factor a kind of waste material extracting platelet cofactor �� from human plasma cryoprecipitate, belong to field of biological pharmacy.
Background technology
VWF is that one has polymeric plasma glycoprotein, and its molecular weight from 250kDa to 2,000 ten thousand kDa not etc., forms maximum molecular weight soluble protein known in blood plasma. Blood plasma small molecular amount vWF is mainly dimeric forms, and molecular weight is about 500kDa. The polymer differed in size, to maintaining, vWF normal biological activity is significant.
Plasma vWF plays an important role in constitutional stops blooding, and it is responsible for the adhesion of platelet and damaged blood vessel surface, and therefore forms platelet plug, contributes to the formation of fibrin crosslinking. It addition, plasma vWF plays a part transport agent and the stabilizer of blood coagulation factor VIII.
Von Willebrand (vWD) is modal hereditary hemorrhagic disease, and (vonWillebrandfactor, the vWF) gene mutation of patient's vWF or regulation and control cause that plasma vWF quantity reduces or abnormal quality extremely. It is hemorrhage that vWD Clinical symptoms is mainly skin mucosa, and 2N type and 3 type patients also can occur the articular cavity similar to hemophilia A hemorrhage and muscle hematoma. According to external, vWD sickness rate (2.3��11.0)/100,000 population, it is considered that in hereditary hemorrhagic disease, vWD occupies second.
The activity Ristocetin co-factor activity (vWF:RCo) of vWF characterizes clinically, is mainly used in treating congenital, Of Acquired von Willebrand Disease (vWD), is generally administered with 20��60UvWF:RCo/kg dosage.
Research shows in cryoprecipitate rich in blood clotting factors materials such as vWF. In today that blood plasma raw material is increasingly in short supply, prepare vWF by cryoprecipitate, the comprehensive utilization to cryoprecipitate, save rare blood plasma resource, improve the market competitiveness and be significant.
In prior art, technique uses the antibody coupling of vWF to agarose gel earlier, by immunoaffinity chromatography purification vWF, but its antibody manufacturing cycle is long, gel carrying capacity is low, the extensive preparation of uncomfortable cooperation, such as " PurificationofvonWillebrandFactorsolutionsusinggelpermea tionchromatography " (UP4774323).
There is patent DEAEFractogelTSK650M (Merck) purification vWF factor component, purity is high, but technics comparing is complicated, need two-step solution and a step affinity chromatograph, such as " Processforanindustrial-scalepreparationofastandardizedhu manvonWillebrandfactorconcentrateofveryhighpurityandsuit ablefortherapeuticuse " (US5408039). Also have been reported that CHT chromatography separates vWF component in conjunction with PH5.4 Acid precipitation, it is not higher than living, and while Acid precipitation removal Fn Fiberonectin, it is likely to affect the biologic activity of vWF, such as " Productionofavonwillebrandfactorprepartionhavingagreatsp ecificactivity " (US20070135619A1).
Some technique EMDFractogelTMAE (Merck) are additionally also had to carry out purification VIII/vWF factor coniplexes, but all cannot individually obtain highly purified vWF, treatment specific aim is not strong, such as " preparation containing vWF with styptic activity and preparation method thereof " (CN1425024A), " AProcessforrecoveringahigh-purityvirus-inactivatedfactor VIIIbyanionexchangerchromatography " (US5714590).
Also has method (monkey-kidney cells or Chinese hamster ovary celI) the purification vWF of some company's gene recombinaton, they are purified from animal cell culture fluid by anion exchange chromatography, but the existence due to animal originality antigen, it is likely to there is repulsive interaction by human body, such as " MethodforisolationofhighlypurevonWillebrandFactor " (US5854403).
Separately having the report adopting two-step chromatography purification vWF, but its purity is not high, more relatively low than living, only 50IU/mg, such as " ProcessformanufacturingvonWillebrandfactor " (US5252710).
Visible, existing vWF purifying process still suffers from some problems: (1) manufacturing cycle is long, is not suitable for extensive preparation, and during in particular by immune-affinity chromatography purification, its antibody manufacturing cycle is long, and gel carrying capacity is low. (2) VIII/vWF composite product is at more difficult control technology stability; (3) recombination method gained vWF product would be likely to occur heterogeneic antigen; (4) separation purifying technique is loaded down with trivial details.
At present, von Willebrand can use cryoprecipitate, VIII/vWF factor coniplexes and DDAVP (DDAVP) treatment, but specific aim is not strong, the purer vWF factor can the various types of von Willebrand of specific therapeutic, have greater advantage with front several method ratio.
Summary of the invention
It is an object of the invention to provide the preparation technology extracting people vWF a kind of waste material extracting platelet cofactor �� from cryoprecipitate.
The major technique design of the present invention is as follows:
The present invention optimizes interpolation 2% gel aluminum hydroxide before S/D inactivation of virus and carries out Adsorption II, VII, IX, X factor; The filter element that before S/D inactivation, cascade filtration uses is of a size of the filter element of 1.0 ��m and 0.45 ��m.
Protein liquid after chromatography is added glycine protection vWF activity by the present invention in chromatography buffer; Protein liquid before lyophilizing adds lysine, glycine and albumin as freeze drying protectant, protection vWF activity after preferred chromatography; Glycine mass concentration 0.6%��1% in preferred chromatography buffer, lysine mass concentration 2��3% in freeze drying protectant, glycine mass concentration 0.2%, albumin mass concentration 0.8��1.3%.
The present invention one step Q-Sepharose anion-exchange chromatography and a step affinitive layer purification obtain the vWF that purity is higher. Namely collect cryoprecipitate extract platelet cofactor �� waste material namely cryoprecipitate extract platelet cofactor �� preparation in through chromatographic column effluent come liquid as raw material; After Q-Sepharose ion-exchange chromatography, collect eluent, then through gelatin affinity chromatograph, remove remaining Fn Fiberonectin and impurity, obtain vWF ELISA.
In the preparation technology of the present invention:
(1) by adjusting the salinity in lavation buffer solution B and elution buffer B; Q-Sepharose column chromatography is adopted to remove Fibrinogen and Fn Fiberonectin and other foreign protein;
(2) eluent after Q-Sepharose column chromatography, then through gelatin chromatography, by adjusting the salinity of elution buffer B and dialysis solution, removes remaining Fn Fiberonectin and impurity, obtains the stream containing high-purity vWF and wear liquid.
The preparation technology of the present invention, it includes successively: cryoprecipitate is dissolved, 2% gel aluminum hydroxide adsorbs, regulate ionic strength, cascade filtration, S/D inactivation of virus, ion-exchange chromatography; Ion-exchange chromatography must collect eluent, and namely eluent, through ultrafiltration, dialysis, filtration, for the production of blood coagulation factor VIII, then collects extraction vWF through the liquid that chromatographic column stream passes from the waste material of cryoprecipitate extraction platelet cofactor ��; Q-Sepharose anion-exchange chromatography, gelatin affinity chromatograph, aseptic filtration subpackage, lyophilization, xeothermic inactivation. After ion-exchange chromatography stream wears liquid collection, first concentration one times, then with lavation buffer solution B equal-volume ultrafiltration 6 times, then through Q-Sepharose chromatographic column, collect the protein liquid eluted with elution buffer B.
The present invention is achieved like this, and its concrete technology scheme is as follows:
(1) after qualified human plasma of quarantining quanrantine is got, 75% ethanol plasma bags surface, to rinse with water for injection, be merged into and melt in slurry tank, melt with less than 30��35 DEG C recirculated waters, blood plasma temperature controls not higher than 4 DEG C; After melting, centrifugal, go out liquid temp and control at 0��4 DEG C, collect cryoprecipitate;
(2) adding in 3IU/ml heparin sodium aqua by the prepared thing of step (1), stirring is completely dissolved to cryoprecipitate, and the temperature of recirculated water controls at 28��37 DEG C; Start to be centrifuged, collect supernatant, weigh;
(3) the prepared thing supernatant 1mol/L hydrochloric acid of step (2) is regulated PH to 6.0��7.0; Add 2% gel aluminum hydroxide, stirring; Start to be centrifuged, collect supernatant, weigh;
(4) calculate by " W (ionic strength buffer liquid)=supernatant weight/10 ", weigh the ionic strength buffer liquid of amount of calculation to the prepared thing supernatant of step (3); Regulate supernatant PH to 6.0��7.0; Regulate protein concentration with protein concentration buffer and be not more than 10g/L; With the filter element filtering of 1.0 ��m, collect filtrate, weigh;
(5) adding S/D solution by the 1/10 of the prepared thing filtrate volume of step (4), stir, temperature controls at 24��26 DEG C, continuously insulation 6 hours; 0.45 ��m of filter element filtering; Filtrate 30KD ultrafilter membrane is concentrated into protein concentration 2%, then with more than 2 times lavation buffer solution A constant volume ultrafiltration of protein liquid weight, obtains ultrafiltrate, weighs;
(6) the prepared thing ultrafiltrate ion exchange column of step (5) is carried out chromatography purification, pillar is washed until becoming baseline with lavation buffer solution A, with elution buffer A eluting, collect eluent (eluent through ultrafiltration, dialysis, filtration, for the production of blood coagulation factor VIII).
(7) collect the liquid that step (6) is come through chromatographic column effluent, concentrate one times, lavation buffer solution B equal-volume ultrafiltration 6 times, obtain ultrafiltrate, weigh.
(8) the prepared thing ultrafiltrate Q-Sepharose anion-exchange chromatography post of step (7) being carried out chromatography purification, washing pillar with lavation buffer solution B until becoming baseline, with elution buffer B eluting, collect eluent, weigh.
(9) the prepared thing eluent gelatin affinity chromatograph of step (8) is purified, pillar is washed until becoming baseline with elution buffer B, the liquid come through chromatographic column effluent after collecting loading, dialyse with dialysis solution, be diluted to titer 100IU/ml, obtain protein liquid, weigh.
(10) by the prepared thing protein liquid of step (9) through 0.2 ��m of degerming filter element filtering subpackage; The incoming lyophilizing cabinet of goods that subpackage is good carries out lyophilization; Offer for sale Zha Gai; 99��100 DEG C, 30 minutes xeothermic inactivation of virus; Censorship, packs after the assay was approved, puts in storage.
The compound method of ionic strength buffer liquid: 48.5g trishydroxymethylaminomethane, 10g calcium chloride, 100g sodium chloride, 28.1g glycine, add appropriate water for injection and fully dissolve, mend and inject water to 1L, regulating PH is 6.0��7.0; The compound method of protein concentration buffer: measure 0.05L and regulate ionic strength buffer liquid, inject water to 1L, regulating PH is 6.0��7.0.
Lavation buffer solution A formula: 2.5g trishydroxymethylaminomethane, 10g calcium chloride, 25g sodium chloride, add appropriate water for injection and fully dissolve, mend and inject water to 1L, regulating PH is 6.0��7.0.
Elution buffer A formula: 2.5g trishydroxymethylaminomethane, 15g calcium chloride, 40.9g sodium chloride, add appropriate water for injection and fully dissolve, mend and inject water to 1L, regulating PH is 6.0��7.0.
The formula of lavation buffer solution B: 4g sodium citrate, 11.4g sodium chloride, 3g calcium chloride, 6g glycine, add appropriate water for injection and fully dissolve, mend and inject water to 1L, regulating PH is 5.8��6.8.
Elution buffer B formula: 4g sodium citrate, 16.38g sodium chloride, 3g calcium chloride, 6g glycine, add appropriate water for injection and fully dissolve, mend and inject water to 1L, regulating PH is 5.8��6.8.
The formula of dialysis solution: 2.94g sodium citrate, 25g sodium chloride, 0.111g calcium chloride, 30g glycine, 2g lysine hydrochloride, human albumin 8g, add appropriate water for injection and fully dissolve, mend and inject water to 1L, regulating PH is 6.8��7.2.
Described percent is except having restriction, and all the other are mass percent.
The positive effect of the present invention:
1, in today that blood plasma raw material is increasingly in short supply, vWF is prepared by cryoprecipitate, making full use of cryoprecipitate, improve the market competitiveness and have great significance, additionally also can the rare blood plasma resource of indirect saving.
2, purify in the process of vWF at ion-exchange chromatography, the solution got off with suitable elution, then through operations such as ultrafiltration, dialysis, filtrations, can be used for producing platelet cofactor ��.
The present invention preparation technology compared to tradition vWF, innovative point is in that:
1. make full use of blood plasma resource, wear waste liquid with the stream of blood coagulation factor VIII ion exchange and prepare high-purity vWF. Waste material such as vWF, Fibrinogen etc. can be produced when producing blood coagulation factor VIII, by the Component seperation in waste material out, turn waste into wealth, utilize blood plasma resource in short supply to greatest extent, improve blood plasma utilization rate.
2, chromatography buffer is added glycine, protein liquid before lyophilizing adds after chromatography lysine, glycine and albumin, protection vWF activity. Chromatography buffer adds glycine the loss of activity of vWF in chromatography purge process, can be reduced. Albumen dialysis solution adds albumin, lysine, glycine as freeze drying protectant, vWF molecule can be stablized. Albumin is excellent protein stabiliser, simultaneously can the absorption of effective protein surface. Lysine, glycine are little molecule aminoacid, it is possible to protected protein matter structure, can raise the collapse temperature of finished product, stop the Protein Damage caused in freeze-drying process because subsiding. Keep biologic activity.
3, ion-exchange chromatography separates the salt ionic concentration that the most critical factor of vWF is cleaning mixture and eluent. The too low meeting of cleaning mixture salinity causes the impurity such as Fibrinogen, Fn Fiberonectin remaining, and cleaning mixture salinity is too high, the response rate causing vWF is reduced, and the vWF amount afforded reduces. Finding after test of many times, 195mM (11.4g/L) sodium chloride is best cleaning mixture salinity. Additionally eluent salt concentration also need in optimum range, and the too high too low acquisition being also unfavorable for vWF, we are defined as 280mM (16.38g/L) by test. The proportioning of both salinity can take into account the activity of vWF and than living, and is best a pair matched proportion density.
4, this technique adopts the exchange of step ion and a step affinity chromatograph technique, both can guarantee that the purity of vWF and yield, it is possible to simplify production technology, fully reduces manpower and time cost. Ion-exchange chromatography plays the effect of preliminary purification, and affinity chromatograph filler has the feature of binding proteins specific, further albumen is carried out polishing purification.
5, adopt the cryoprecipitate of humanized as initiation material, it is to avoid the generation of the heterogeneic antigen rejection of recombiant protein, improve Clinical practice safety.
Accompanying drawing explanation
Fig. 1 is present invention process flow chart.
It is embodied as case
The present invention by the following examples can the invention will be further described, but, the scope of the present invention is not limited to following embodiment.
For 6000L blood plasma, concrete preparation technology is as follows:
(1) after qualified human plasma of quarantining quanrantine is got, 75% ethanol plasma bags surface, to rinse with water for injection, be merged into and melt in slurry tank, melt with less than 30��35 DEG C recirculated waters, blood plasma temperature controls not higher than 4 DEG C; After melting, centrifugal, go out liquid temp and control, at 0��4 DEG C, to collect to obtain cryoprecipitate 45.2kg;
(2) adding in 3IU/ml heparin sodium aqua by the prepared thing cryoprecipitate of step (1), stirring is completely dissolved to cryoprecipitate, and the temperature of recirculated water controls at 28��37 DEG C; Starting to be centrifuged, collect supernatant, weigh to obtain 169.5kg;
(3) the prepared thing supernatant 1mol/LHCL of step (2) is regulated PH to 6.0��7.0; Add 2% gel aluminum hydroxide, stirring; Starting to be centrifuged, collect supernatant, weigh to obtain 178.6kg;
(4) calculate by " W (ionic strength buffer liquid)=supernatant weight/10 ", weigh the ionic strength buffer liquid of amount of calculation to the prepared thing supernatant of step (3); Regulate supernatant PH to 6.0��7.0; Regulate protein concentration with protein concentration buffer and be not more than 10g/L; Filtering after connecting with the filter element of the filter elements of 1.0 ��m and 0.45 ��m, collect filtrate, weigh to obtain 189.9kg;
(5) adding S/D solution by the 1/10 of the prepared thing filtrate volume of step (4), stir, temperature controls at 24��26 DEG C, continuously insulation 6 hours; 0.45 ��m of filter element filtering; Filtrate 30KD ultrafilter membrane is concentrated into protein concentration about 2%, and then with more than 2 times lavation buffer solution A constant volume ultrafiltration of protein liquid weight, i.e. ultrafiltrate, weigh to obtain 201.4L;
(6) the prepared thing ultrafiltrate ion exchange column of step (5) being carried out chromatography purification, washing pillar with lavation buffer solution A until becoming baseline, with elution buffer A eluting, collect eluent.
(7) collect the liquid that step (6) is come through chromatographic column effluent, concentrate one times, lavation buffer solution B equal-volume ultrafiltration 6 times, obtain ultrafiltrate, weigh to obtain 120.5L;
(8) the prepared thing ultrafiltrate Q-Sepharose anion-exchange chromatography post of step (7) being carried out chromatography purification, washing pillar with lavation buffer solution B until becoming baseline, with elution buffer B eluting, collect eluent, weigh to obtain 48.5L;
(9) the prepared thing eluent gelatin affinity chromatograph of step (8) being purified, washing pillar with elution buffer B until becoming baseline, the liquid come through chromatographic column effluent after collecting loading, it is concentrated by ultrafiltration to 5L, dialysing 6 times, obtain ultrafiltrate, weigh to obtain 5.2L; It is assigned to 6.1L by titer 100IU/ml is rare;
(10) by the prepared thing filtrate of step (9) through 0.2 ��m of degerming filter element filtering subpackage, subpackage loading amount is every bottle of 5mL, and subpackage quantity is 1196 bottles; The incoming lyophilizing cabinet of goods that subpackage is good carries out lyophilization; Offer for sale Zha Gai; 99��100 DEG C, 30 minutes xeothermic inactivation of virus; Censorship, packs after the assay was approved, puts in storage;
Described percent is except having restriction, and all the other are mass percent.
The contrast such as table 1 below of the vWF Key Quality Indicator that product prepared by the inventive method and " in European Pharmacopoeia " describe.
Table 1:
| Project | The present invention | " European Pharmacopoeia " |
| PH | 6.8��7.2 | 6.5��7.5 |
| Activity | Should >=100IU/ml | ��1IU/ml |
| Than living | Should >=200IU/mg | ��20IU/mg |
| Blood coagulation factor VIII content | VIII:C 2��4IU/ml in every 100IU vWF:RCo | VIII:C��10IU/ml in every 100IUvWF:RCo |
| Osmotic pressure molar density | 240��1000mOsmol/kg | 240mOsmol/kg should be not less than |
In product prepared by the inventive method, the lab scale of the impact of product quality is studied by different ion exchange salinity, such as table 2 below.
Table 2:
Illustrate: in anion exchange procedures, vWF and Fn Fiberonectin are interval in this salinity of 150mMNaCl to 300mMNaCl, salinity and ionic strength is very sensitive, through Experimental Comparison analysis, screening obtains the column buffer formula of liquid that two kinds of major impurities (Fn Fiberonectin and Fibrinogen) are minimum. Preferred cleaning mixture is 195mMNaCl (11.4g/L) and eluent is 280mM (16.38g/L) NaCl, can obtain activity and than all higher vWF that lives.
In product prepared by the inventive method, the glycine impact on product in chromatography buffer, such as table 3.
Table 3:
| Glycine concentration (%) | Cleaning mixture belit concentration (%) | Eluent belit concentration (%) | VWF:RCo activity (IU/ml) |
| 0 | 195 | 280 | 101.5 |
| 0.2 | 195 | 280 | 102.1 |
| 0.6 | 195 | 280 | 104.8 |
| 1.0 | 195 | 280 | 104.81 |
Illustrate: the glycine in chromatography buffer in chromatography process, can protect the effect in vWF, mass concentration 0.6%��1%, and the protective effect of chromatography process vWF is more or less the same by the glycine concentration of this scope, select relatively low, it is still further preferred that 0.6%.
In product prepared by the inventive method, the impact on product of dialysis solution (frozen-dried protective liquid) the various heterogeneity, such as table 4.
Table 4:
Illustrating: glycine mass concentration 2��3%, lysine mass concentration 0.2%, albumin mass concentration 0.8��1.3%, for the good scope of application, outward appearance is slightly or without atrophy, and has slight or without opalescence, activity is also better protected. The difference of the mass concentration of lysine is less on frozen-dried protective impact, selects 0.2%. Best dialysis buffer liquid (frozen-dried protective liquid) formula is glycine concentration is 3%, and albumin concentration is 0.8%, and outward appearance and activity are the best.
Claims (10)
1. the preparation technology extracting vWF ELISA from the waste material of cryoprecipitate extraction platelet cofactor ��, it is characterized in that, obtain, with a step Q-Sepharose anion-exchange chromatography and a step affinitive layer purification, the vWF that purity is higher: collect cryoprecipitate extract platelet cofactor �� waste material namely cryoprecipitate extract platelet cofactor �� preparation in through chromatographic column effluent come liquid as raw material; After Q-Sepharose ion-exchange chromatography, collect eluent, then through gelatin affinity chromatograph, remove remaining Fn Fiberonectin and impurity, obtain vWF ELISA.
2. a kind of waste material extracting platelet cofactor �� from cryoprecipitate according to claim 1 extracts the preparation technology of vWF ELISA, it is characterized in that, cryoprecipitate extract platelet cofactor �� preparation technology include: cryoprecipitate dissolvings, gel adsorption, adjustment ionic strength, cascade filtration, S/D inactivate, ion-exchange chromatography; Ion-exchange chromatography collects eluent, and eluent is through ultrafiltration, dialysis, filtration, for the production of blood coagulation factor VIII; Gel adsorption before inactivateing preferably in S/D is adsorbed for adding 2% gel aluminum hydroxide.
3. the preparation technology extracting vWF ELISA from the waste material of cryoprecipitate extraction platelet cofactor ��, it is characterized in that, collect cryoprecipitate extract platelet cofactor �� waste material namely cryoprecipitate extract platelet cofactor �� preparation in through chromatographic column effluent come liquid as raw material; In the preparation technology of vWF ELISA, the protein liquid after chromatography is added in chromatography buffer glycine protection vWF activity; Protein liquid before lyophilizing adds lysine, glycine and albumin as freeze drying protectant, protection vWF activity after preferred chromatography; Glycine mass concentration 0.6%��1% in preferred chromatography buffer, lysine mass concentration 2��3% in freeze drying protectant, glycine mass concentration 0.2%, albumin mass concentration 0.8��1.3%.
4. a kind of waste material extracting platelet cofactor �� from cryoprecipitate according to claim 1,2 or 3 extracts the preparation technology of vWF ELISA, it is characterised in that
(1) by adjusting the salinity in lavation buffer solution B and elution buffer B; Q-Sepharose column chromatography is adopted to remove Fibrinogen and Fn Fiberonectin and other foreign protein;
(2) eluent after Q-Sepharose column chromatography, then through gelatin chromatography, by adjusting the salinity of elution buffer B and dialysis solution, removes remaining Fn Fiberonectin and impurity, obtains the stream containing high-purity vWF and wear liquid.
5. a kind of waste material extracting platelet cofactor �� from cryoprecipitate according to claim 2 extracts the preparation technology of vWF ELISA, it is characterised in that the filter element that before S/D inactivation, cascade filtration uses is of a size of the filter element of 1.0 ��m and 0.45 ��m.
6. a kind of waste material extracting platelet cofactor �� from cryoprecipitate according to claim 2 extracts the preparation technology of vWF ELISA, it is characterized in that, after ion-exchange chromatography stream wears liquid collection, first concentration one times, again with lavation buffer solution B equal-volume ultrafiltration 6 times, then through Q-Sepharose chromatographic column, collect the protein liquid eluted with elution buffer B.
7. a kind of waste material extracting platelet cofactor �� from cryoprecipitate according to claim 4 extracts the preparation technology of vWF ELISA, it is characterized in that, the formula of described lavation buffer solution B: 4g sodium citrate, 11.4g sodium chloride, 3g calcium chloride, 6g glycine, add appropriate water for injection and fully dissolve, benefit injects water to 1L, and regulating pH is 5.8��6.8.
8. a kind of waste material extracting platelet cofactor �� from cryoprecipitate according to claim 4 extracts the preparation technology of vWF ELISA, it is characterized in that, described elution buffer B formula: 4g sodium citrate, 16.38g sodium chloride, 3g calcium chloride, 6g glycine, add appropriate water for injection and fully dissolve, benefit injects water to 1L, and regulating pH is 5.8��6.8.
9. a kind of waste material extracting platelet cofactor �� from cryoprecipitate according to claim 4 extracts the preparation technology of vWF ELISA, it is characterized in that, described dialysis solution formula: 2.94g sodium citrate, 25g sodium chloride, 0.111g calcium chloride, 30g glycine, 2g lysine hydrochloride, human albumin 8g, add appropriate water for injection and fully dissolve, benefit injects water to 1L, and regulating pH is 6.8��7.2.
10. a kind of waste material extracting platelet cofactor �� from cryoprecipitate according to claim 1 extracts the preparation technology of vWF ELISA, it is characterised in that preparation technology is as follows:
(1) cryoprecipitate is collected;
(2) adding in 3IU/ml heparin sodium aqua by the cryoprecipitate of step (1), stirring is completely dissolved to cryoprecipitate, and the temperature of recirculated water controls at 28��37 DEG C; Start to be centrifuged, collect supernatant, weigh;
(3) the prepared thing supernatant 1mol/LHCL of step (2) is regulated pH to 6.0��7.0; Add 2% gel aluminum hydroxide, stirring; Start to be centrifuged, collect supernatant, weigh;
(4) calculate by " regulating ionic strength buffer liquid W=supernatant weight/10 ", weigh the adjustment ionic strength buffer liquid of amount of calculation to the prepared thing supernatant of step (3); Regulate supernatant pH to 6.0��7.0; It is not more than 10g/L with regulating protein concentration buffer adjustment protein concentration; With the filter element cascade filtration of the filter elements of 1.0 ��m and 0.45 ��m, collect filtrate, weigh;
(5) adding S/D solution by the 1/10 of the prepared thing filtrate volume of step (4), stir, temperature controls at 24��26 DEG C, continuously insulation 6 hours; 0.45 ��m of filter element filtering; Filtrate 30KD ultrafilter membrane is concentrated into protein concentration 2%, then with more than 2 times lavation buffer solution A constant volume ultrafiltration of protein liquid weight, obtains ultrafiltrate, weighs;
(6) the prepared thing ultrafiltrate ion exchange column of step (5) being carried out chromatography purification, washing pillar with lavation buffer solution A until becoming baseline, with elution buffer A eluting, collect eluent;
(7) collect the liquid that step (6) is come through chromatographic column effluent, concentrate one times, lavation buffer solution B equal-volume ultrafiltration 6 times, obtain ultrafiltrate, weigh;
(8) the prepared thing ultrafiltrate Q-Sepharose anion-exchange chromatography post of step (7) being carried out chromatography purification, washing pillar with lavation buffer solution B until becoming baseline, with elution buffer B eluting, collect eluent, weigh;
(9) the prepared thing eluent gelatin affinity chromatograph of step (8) is purified, pillar is washed until becoming baseline with elution buffer B, the liquid come through chromatographic column effluent after collecting loading, dialyse with dialysis solution, be diluted to titer 100IU/ml, obtain protein liquid, weigh;
(10) by the prepared thing protein liquid of step (9) through 0.2 ��m of degerming filter element filtering subpackage; The incoming lyophilizing cabinet of goods that subpackage is good carries out lyophilization; Offer for sale Zha Gai; 99��100 DEG C, 30 minutes xeothermic inactivation of virus; Censorship, packs after the assay was approved, puts in storage;
Described percent is except having restriction, and all the other are mass percent;
Preferred: the formula regulating ionic strength buffer liquid described in step (4): the compound method of ionic strength buffer liquid: 48.5g trishydroxymethylaminomethane, 10g calcium chloride, 100g sodium chloride, 28.1g glycine, add appropriate water for injection fully to dissolve, benefit injects water to 1L, and regulating pH is 6.0��7.0; The compound method of protein concentration buffer: measure 0.05L and regulate ionic strength buffer liquid, inject water to 1L, regulating pH is 6.0��7.0;
Preferred: the formula of the lavation buffer solution A described in step (5): 2.5g trishydroxymethylaminomethane, 10g calcium chloride, 25g sodium chloride, add appropriate water for injection and fully dissolve, mend and inject water to 1L, regulating pH is 6.0��7.0;
Preferred: the elution buffer A formula described in step (6): 2.5g trishydroxymethylaminomethane, 15g calcium chloride, 40.9g sodium chloride, add appropriate water for injection and fully dissolve, mend and inject water to 1L, regulating pH is 6.0��7.0.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610077346.0A CN105622746A (en) | 2016-02-04 | 2016-02-04 | Preparation process for extracting human von Willebrand factor from waste of cryoprecipitate extraction blood coagulation factor VIII |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610077346.0A CN105622746A (en) | 2016-02-04 | 2016-02-04 | Preparation process for extracting human von Willebrand factor from waste of cryoprecipitate extraction blood coagulation factor VIII |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105622746A true CN105622746A (en) | 2016-06-01 |
Family
ID=56038127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610077346.0A Pending CN105622746A (en) | 2016-02-04 | 2016-02-04 | Preparation process for extracting human von Willebrand factor from waste of cryoprecipitate extraction blood coagulation factor VIII |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105622746A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107857811A (en) * | 2017-12-20 | 2018-03-30 | 广东丹霞生物制药有限公司 | A kind of preparation technology of human serum albumin |
| CN107880112A (en) * | 2017-12-28 | 2018-04-06 | 华兰生物工程股份有限公司 | A kind of human blood coagulation factor VII I preparation method and human blood coagulation factor VII I products |
| CN109705208A (en) * | 2018-12-29 | 2019-05-03 | 山东泰邦生物制品有限公司 | A kind of technique of single step chromatography preparation high-purity vWF ELISA |
| CN110997015A (en) * | 2017-08-23 | 2020-04-10 | 德国杰特贝林生物制品有限公司 | Methods for viral filtration of von Willebrand factor |
| CN111491949A (en) * | 2017-10-27 | 2020-08-04 | 株式会社绿十字控股 | Method for preparing a composition comprising factor 8 capable of controlling the content of Von Willebrand Factor (VWF) and von Willebrand factor |
| CN111592591A (en) * | 2020-06-17 | 2020-08-28 | 博雅生物制药集团股份有限公司 | Preparation method of human von willebrand factor/human blood coagulation factor VIII compound, product and application |
| CN113045634A (en) * | 2019-12-28 | 2021-06-29 | 四川远大蜀阳药业有限责任公司 | Preparation method of complement H factor |
| CN114249812A (en) * | 2020-09-22 | 2022-03-29 | 四川远大蜀阳药业有限责任公司 | Method for reducing IgM content in vWF product |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5408039A (en) * | 1991-03-08 | 1995-04-18 | Centre Regional De Transfusion Sanguine De Lille | Process for an industrial-scale preparation of a standardized human von Willebrand factor concentrate of very high purity and suitable for therapeutic use |
| CA2009946C (en) * | 1989-02-14 | 2000-04-11 | Norbert Heimburger | Pasteurized, purified von willebrand factor concentrate and a process for the preparation thereof |
| WO2010082184A1 (en) * | 2009-01-19 | 2010-07-22 | Kedrion S.P.A. | New process for highly selective purification of two plasma proteins: von willebrand factor (vwf) and fibronectin (fn) |
| CN104231072A (en) * | 2014-10-09 | 2014-12-24 | 江西博雅生物制药股份有限公司 | Preparation process for extracting human fibrinogens from waste for extracting cryoprecipitated blood coagulation factor VIII |
-
2016
- 2016-02-04 CN CN201610077346.0A patent/CN105622746A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2009946C (en) * | 1989-02-14 | 2000-04-11 | Norbert Heimburger | Pasteurized, purified von willebrand factor concentrate and a process for the preparation thereof |
| US5408039A (en) * | 1991-03-08 | 1995-04-18 | Centre Regional De Transfusion Sanguine De Lille | Process for an industrial-scale preparation of a standardized human von Willebrand factor concentrate of very high purity and suitable for therapeutic use |
| WO2010082184A1 (en) * | 2009-01-19 | 2010-07-22 | Kedrion S.P.A. | New process for highly selective purification of two plasma proteins: von willebrand factor (vwf) and fibronectin (fn) |
| CN104231072A (en) * | 2014-10-09 | 2014-12-24 | 江西博雅生物制药股份有限公司 | Preparation process for extracting human fibrinogens from waste for extracting cryoprecipitated blood coagulation factor VIII |
Non-Patent Citations (2)
| Title |
|---|
| 余 氵贺，等: "《临床免疫技术》", 28 February 1982, 上海科学技术出版社 * |
| 陈玉祥编著: "《分子药剂学》", 31 January 2010, 长沙：湖南师范大学出版社 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110997015A (en) * | 2017-08-23 | 2020-04-10 | 德国杰特贝林生物制品有限公司 | Methods for viral filtration of von Willebrand factor |
| CN111491949A (en) * | 2017-10-27 | 2020-08-04 | 株式会社绿十字控股 | Method for preparing a composition comprising factor 8 capable of controlling the content of Von Willebrand Factor (VWF) and von Willebrand factor |
| CN111491949B (en) * | 2017-10-27 | 2024-01-09 | 株式会社绿十字控股 | Method for preparing a composition containing Factor VIII (FVIII) and von willebrand factor with controlled amounts of Von Willebrand Factor (VWF) |
| CN107857811A (en) * | 2017-12-20 | 2018-03-30 | 广东丹霞生物制药有限公司 | A kind of preparation technology of human serum albumin |
| CN107880112A (en) * | 2017-12-28 | 2018-04-06 | 华兰生物工程股份有限公司 | A kind of human blood coagulation factor VII I preparation method and human blood coagulation factor VII I products |
| CN109705208A (en) * | 2018-12-29 | 2019-05-03 | 山东泰邦生物制品有限公司 | A kind of technique of single step chromatography preparation high-purity vWF ELISA |
| CN109705208B (en) * | 2018-12-29 | 2022-04-26 | 山东泰邦生物制品有限公司 | Process for preparing high-purity von willebrand factor by single-step chromatography |
| CN113045634A (en) * | 2019-12-28 | 2021-06-29 | 四川远大蜀阳药业有限责任公司 | Preparation method of complement H factor |
| CN113045634B (en) * | 2019-12-28 | 2023-04-28 | 四川远大蜀阳药业有限责任公司 | Preparation method of complement factor H |
| CN111592591A (en) * | 2020-06-17 | 2020-08-28 | 博雅生物制药集团股份有限公司 | Preparation method of human von willebrand factor/human blood coagulation factor VIII compound, product and application |
| CN114249812A (en) * | 2020-09-22 | 2022-03-29 | 四川远大蜀阳药业有限责任公司 | Method for reducing IgM content in vWF product |
| CN114249812B (en) * | 2020-09-22 | 2023-09-15 | 四川远大蜀阳药业有限责任公司 | Method for reducing IgM content in vWF (vWF) product |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105622746A (en) | Preparation process for extracting human von Willebrand factor from waste of cryoprecipitate extraction blood coagulation factor VIII | |
| RU2088590C1 (en) | Method of preparing the standardized concentration of human villebrand factor and concentrate obtained by this method | |
| US3631018A (en) | Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate | |
| US4341764A (en) | Method of preparing fibronectin and antihemophilic factor | |
| CN102584983B (en) | Method for separating and purifying blood coagulation factor VIII | |
| HU214905B (en) | Process for isolating factor viii | |
| RU2603103C2 (en) | Method of producing fibrinogen using strong anion exchange resin and fibrinogen-containing product | |
| JPH11509721A (en) | How to obtain high purity von Willebrand factor | |
| CN107226859B (en) | Preparation method of human blood coagulation factor VIII | |
| CN105622747A (en) | vWF (von Willebrand factor) activity protection fluid | |
| TW200918145A (en) | Method for purifying factor VIII and von willebrand factor | |
| CN103153333B (en) | The purification process of complement factor H | |
| CN105330736A (en) | Method for preparing human blood coagulation factors IX and VII subcutaneously from cold-glue-removed blood plasma | |
| JP2001513088A (en) | Purification of von Willebrand factor by cation exchange chromatography | |
| CN113563457A (en) | Method for simultaneously preparing human fibrinogen, blood coagulation factor VIII and plasminogen | |
| AU635535B2 (en) | Gel filtration of heat treated factor viii | |
| US4455300A (en) | Fibronectin compositions | |
| CN111592591B (en) | Preparation method of human von willebrand factor/human blood coagulation factor VIII compound, product and application | |
| JP2000506843A (en) | Filtration of plasma mixtures using cellulosic filter aids | |
| CN107880112B (en) | Preparation method of human blood coagulation factor VIII and human blood coagulation factor VIII product | |
| EP2387582B1 (en) | New process for highly selective purification of two plasma proteins: von willebrand factor (vwf) and fibronectin (fn) | |
| EP3404037B1 (en) | Method for purifying fibrinogen | |
| CN105481976B (en) | Washing buffer solution for ion exchange chromatography for preparing human coagulation factor VIII and application thereof | |
| CN104292341B (en) | A kind of eight factor fusion protein of blood coagulation and its preparation method and application | |
| CN105541997A (en) | Preparation process of high-purity and high-activity von Willebrand factors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Liang Xiaoming Inventor after: He Shuqin Inventor after: Huang Yi Inventor after: Yang Zhi Inventor after: Liu Yuliang Inventor after: Kuang Qingfen Inventor before: Yang Ducai Inventor before: Liang Xiaoming Inventor before: He Shuqin Inventor before: Yang Zhi Inventor before: Liu Yuliang Inventor before: Kuang Qingfen |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160601 |